Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors

Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors

Peptide receptor radionuclide therapy (PRRT) is an established treatment in advanced neuroendocrine tumors (NETs), which overexpressed somatostatin receptors. However, after progression there are a limited number of available treatments. We want to share a case report about a patient with a NET re-t...

Full description

Bibliographic Details
Main Authors: Elena María Vida Navas, Alberto Martínez Lorca, Aintzane Sancho Gutiérrez, Lucia Sanz Gómez, Teresa Navarro Martínez, Enrique Grande Pulido, Alfredo Carrato Mena, Pablo Gajate Borau
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-04-01
Series:Frontiers in Endocrinology
Subjects:
neuroendocrine tumors
Lu-DOTATATE
neuroendocrine neoplasms
peptide receptor radionuclide therapy
case report
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2021.676973/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2021.676973/full

Similar Items